Norris Perne & French LLP MI Buys 996 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Norris Perne & French LLP MI increased its stake in Thermo Fisher Scientific Inc. by 3.9% during Q2, acquiring an additional 996 shares, bringing their total to 26,397 shares valued at approximately $10.7 million.
• Several institutional investors have also increased their holdings in Thermo Fisher, with Vanguard Group Inc. now owning over 33.4 million shares, valued at around $16.66 billion.
• Equities analysts have varying price targets for Thermo Fisher, with a consensus rating of "Moderate Buy" and an average price target of approximately $588.35.

Norris Perne & French LLP MI raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 3.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,397 shares of the medical research company's stock after acquiring an additional 996 shares during the period. Norris Perne & French LLP MI's holdings in Thermo Fisher Scientific were worth $10,703,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Vanguard Group Inc. increased its holdings in Thermo Fisher Scientific by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 33,479,957 shares of the medical research company's stock valued at $16,659,627,000 after acquiring an additional 230,382 shares during the last quarter. Amundi grew its stake in shares of Thermo Fisher Scientific by 5.9% in the 1st quarter. Amundi now owns 3,029,044 shares of the medical research company's stock worth $1,426,316,000 after buying an additional 168,197 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Thermo Fisher Scientific by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,925,591 shares of the medical research company's stock worth $1,455,774,000 after buying an additional 115,463 shares in the last quarter. Pictet Asset Management Holding SA grew its stake in shares of Thermo Fisher Scientific by 7.2% in the 1st quarter. Pictet Asset Management Holding SA now owns 2,879,274 shares of the medical research company's stock worth $1,432,816,000 after buying an additional 193,378 shares in the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in shares of Thermo Fisher Scientific by 13.6% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company's stock worth $1,368,859,000 after buying an additional 329,974 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on TMO shares. Evercore ISI dropped their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Wells Fargo & Company dropped their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Scotiabank raised shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research note on Friday, July 11th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Finally, HSBC reaffirmed a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $588.35.

Insider Buying and Selling

In related news, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 30,066 shares of company stock worth $14,182,963 in the last 90 days. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 1.1%

NYSE:TMO opened at $464.18 on Monday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $623.77. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93. The firm has a market cap of $175.28 billion, a P/E ratio of 26.85, a P/E/G ratio of 2.52 and a beta of 0.75. The firm has a 50-day simple moving average of $476.70 and a 200-day simple moving average of $447.15.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's quarterly revenue was up 2.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's payout ratio is 9.95%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.